Gastroenteropancreatic Neuroendocrine Tumors: Advances in Treatment and Management

Gastroenteropancreatic NETs: A Growing Clinical Challenge?

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogeneous group of neoplasms that have witnessed a steady increase in incidence over recent decades, largely attributed to advancements in diagnostic imaging technologies such as endoscopic ultrasound, multi-phase computed tomography, and magnetic resonance imaging. These tumors, once considered rare, now present significant clinical challenges due to their diverse biological behavior, varied clinical presentations, and complex management requirements. The clinical landscape of GEP-NETs is characterized by significant heterogeneity, with tumors ranging from indolent, slow-growing lesions to highly aggressive variants that can cause substantial morbidity and mortality. Approximately 50% of patients present with metastatic disease at diagnosis, underscoring the critical need for effective systemic therapeutic approaches beyond traditional surgical interventions. The treatment paradigm has evolved considerably, with the integration of somatostatin analogs, targeted therapies, peptide receptor radionuclide therapy (PRRT), and various chemotherapeutic regimens now forming the backbone of clinical management strategies for patients with advanced or metastatic disease. Recent advancements in molecular profiling and biomarker development have further refined our understanding of tumor biology and opened new avenues for precision medicine approaches in this challenging disease spectrum.

What Drives the Biology of These Tumors?

The pathophysiology of GEP-NETs involves a complex interplay of genetic, epigenetic, and molecular alterations that disrupt normal cellular mechanisms. Mutations in key regulatory genes such as MEN1, DAXX, and ATRX, along with dysregulation of critical signaling pathways like PI3K/AKT/mTOR and Wnt/β-catenin, contribute to uncontrolled tumor cell growth and metastasis. Small bowel neuroendocrine tumors (sbNETs) typically demonstrate a relatively low mutation rate but frequently exhibit chromosome 18 loss and CDKN1B alterations. A distinguishing feature of GEP-NETs is their pronounced vascularity, with intratumoral blood vessel density approximately 10-fold higher than many other carcinomas, influencing their biological behavior and treatment response. The tumor microenvironment plays a crucial role in supporting GEP-NET progression, with angiogenesis driven by various factors including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β). Additionally, overexpression of somatostatin receptor subtype 2 (SSTR2) represents a hallmark of many GEP-NETs, serving as both a critical component of tumor biology and a therapeutic target for treatments such as somatostatin analogs and radioligand therapies. The World Health Organization classifies NETs based on histologic differentiation and proliferative index, dividing them into three grades that reflect tumor aggressiveness and guide treatment decisions: low-grade (G1, Ki-67 <3%), intermediate-grade (G2, Ki-67 3-10%), and high-grade (G3, Ki-67 >20%).

How Do GEP-NETs Manifest Clinically?

The clinical presentation of GEP-NETs varies significantly between localized and metastatic disease. In localized settings, patients may be entirely asymptomatic, with tumors discovered incidentally during routine imaging or endoscopic procedures. When symptoms do appear, they are typically nonspecific, including abdominal pain, mild gastrointestinal disturbances, or subtle changes in bowel habits. Functional tumors, even when localized, can present with distinct clinical syndromes based on their hormone secretion patterns: insulinomas may cause hypoglycemic episodes, gastrinomas can result in severe peptic ulcer disease (Zollinger-Ellison syndrome), and VIPomas may lead to severe diarrhea and electrolyte imbalances. At diagnosis, nearly 50% of GEP-NETs are already metastatic, with symptomatology becoming broader and more severe. Common manifestations in metastatic disease include significant weight loss, fatigue, and worsening abdominal symptoms. Liver metastases often lead to carcinoid syndrome, characterized by episodic flushing, diarrhea, wheezing, and potential right-sided heart valve problems due to vasoactive substances such as 5-HIAA entering systemic circulation. Organ-specific symptoms may also develop, such as hepatomegaly and right upper quadrant pain with liver involvement, bone pain with skeletal metastases, and lymphadenopathy with lymph node spread.

Can Recent Trials Inform Future Therapies?

The landscape of clinical trials in GEP-NETs has expanded dramatically in recent years, with several landmark studies reshaping treatment paradigms. The PROMID and CLARINET trials established the antiproliferative efficacy of somatostatin analogs (SSAs) in well-differentiated GEP-NETs. In the PROMID study, octreotide LAR demonstrated significant clinical benefit with a median progression-free survival (mPFS) of 14.3 months compared to 6 months with placebo (hazard ratio [HR] 0.34; p<0.001) and a disease control rate of 66.7%. Similarly, the CLARINET trial showed that lanreotide extended mPFS to 32.8 months versus 18 months for placebo (HR 0.47; p<0.001) with a remarkable disease control rate of 87%. These pivotal trials established SSAs as the cornerstone of first-line therapy for well-differentiated, low-to-intermediate grade GEP-NETs with positive somatostatin receptor expression. Beyond SSAs, targeted therapies such as the mTOR inhibitor everolimus have demonstrated significant efficacy in the RADIANT-3 trial, extending mPFS to 11.0 months versus 4.6 months with placebo (HR 0.35; p<0.001) in patients with metastatic G1 and G2 pancreatic NETs after progression on SSAs. The RADIANT-4 trial subsequently confirmed the efficacy of everolimus in G1 and G2 advanced small bowel NETs, showing a mPFS of 11.0 months compared to 3.9 months with placebo, further expanding the therapeutic options available for patients with progressive disease.

Is PRRT the Game Changer in GEP-NET Treatment?

The introduction of peptide receptor radionuclide therapy (PRRT) has revolutionized the treatment landscape for patients with SSTR-positive GEP-NETs. The pivotal phase III NETTER-1 trial evaluated (177Lu)Lu-DOTATATE in patients with progressive midgut NETs and demonstrated a remarkable improvement in mPFS to 28.4 months compared to 8.5 months with high-dose octreotide (HR 0.21; p<0.001). This groundbreaking study led to regulatory approval and established PRRT as a standard treatment option for patients with SSTR-positive, progressive disease. Building on this success, the NETTER-2 trial has expanded the evaluation of (177Lu)Lu-DOTATATE to newly diagnosed, higher-grade (G2 with Ki-67 >10% and G3 ≤55%) GEP-NETs. Preliminary results from NETTER-2 indicate that the trial met its primary endpoint with improved PFS of 22.8 months compared to 8.5 months and an impressive objective response rate of 43%. These findings suggest that earlier implementation of PRRT in the treatment sequence may provide substantial clinical benefit for patients with higher-grade disease. Novel radioligand agents are also under investigation, including alpha-emitting radionuclides such as Actinium-225 (225Ac)DOTATATE (RYZ101) and (212Pb)DOTAMTATE, which offer high cytotoxic potency with shorter tissue penetration, potentially enhancing efficacy against micro-metastatic disease while minimizing collateral damage to surrounding healthy tissues.

Which Therapy Comes First? Evaluating Treatment Sequencing

The optimal sequencing of available therapies remains a critical clinical question in the management of advanced GEP-NETs, leading to several comparative trials designed to address this knowledge gap. The NETRetreat trial is comparing retreatment with (177Lu)Lu-DOTATATE PRRT to everolimus in patients who have previously received (177Lu)Lu-DOTATATE for metastatic midgut NETs. The ComPareNET trial is directly comparing capecitabine plus temozolomide (CAPTEM) to (177Lu)Lu-DOTATATE in advanced pancreatic NETs, addressing the question of which approach provides superior efficacy and tolerability in the frontline setting. The COMPETE trial is evaluating (177Lu)Lu-Edotreotide versus everolimus in patients with advanced SSTR-positive GEP-NETs, with preliminary results showing a mPFS advantage of 23.9 months versus 14.1 months favoring the radioligand approach. Similarly, the COMPOSE trial is assessing (177Lu)Lu-Edotreotide against best standard of care (including chemotherapy or everolimus) in patients with high-grade G2 and G3 SSTR-positive GEP-NETs. These comparative studies will provide crucial evidence to inform clinical decision-making regarding the optimal positioning of different therapeutic modalities within the treatment algorithm. Additionally, innovative combination strategies are being explored to enhance the efficacy of radioligand therapy, including combinations with DNA repair enzyme inhibitors such as peposertib, triapine, and olaparib, which may potentiate the DNA-damaging effects of radiation and overcome resistance mechanisms.

Do Tyrosine Kinase Inhibitors Offer a New Hope?

In the realm of targeted therapies, tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy in GEP-NETs by exploiting their highly vascular nature. Sunitinib, a multi-tyrosine kinase inhibitor, received FDA approval for metastatic pancreatic NETs based on the SUN111 trial, which showed improved mPFS (11.4 months versus 5.5 months; HR 0.42; p<0.001) and achieved an objective response rate of 9.3%. More recently, cabozantinib, another multi-tyrosine kinase inhibitor evaluated in the phase III CABINET trial, demonstrated remarkable efficacy in both pancreatic and extrapancreatic NETs after progression on two prior lines of treatment. In pancreatic NETs, cabozantinib extended mPFS to 13.8 months versus 4.4 months with placebo (HR 0.23; p<0.001) and achieved an objective response rate of 18%, double that of sunitinib. In extrapancreatic NETs, cabozantinib showed a mPFS of 8.4 months versus 3.9 months (HR 0.38; p<0.001), leading to FDA approval in both settings and establishing cabozantinib as the only TKI approved for advanced progressive small bowel NETs. The higher response rate of cabozantinib compared to sunitinib is attributed to its broader inhibition profile targeting multiple kinases including MET and AXL. Next-generation TKIs such as zanzalintinib (XL092) are now entering clinical development, with the STELLAR-311 trial planned to evaluate this agent against everolimus as firstline therapy in advanced NETs regardless of site of origin.

Can Chemotherapy Still Make an Impact?

Chemotherapy continues to play an important role in the management of GEP-NETs, particularly for pancreatic NETs with higher proliferation indices or substantial disease burden requiring rapid response. The ECOG-ACRIN E2211 trial, a multicenter, randomized phase II study in patients with advanced, low- or intermediate-grade pancreatic NETs, compared temozolomide monotherapy to the combination of capecitabine plus temozolomide (CAPTEM). This landmark study demonstrated significantly longer mPFS with CAPTEM at 22.7 months versus 14.4 months with temozolomide alone (HR 0.58; p=0.022). Final analysis showed a clinically meaningful but non-statistically significant OS benefit (median 58.7 versus 53.8 months; HR 0.82; p=0.42). Both regimens achieved robust objective response rates: 40% with CAPTEM and 34% with temozolomide monotherapy. Based on these findings, CAPTEM has become a standard chemotherapeutic approach for pancreatic NETs in clinical practice, although it has not received formal FDA approval. The ongoing S2104 trial is now evaluating the potential role of CAPTEM in the adjuvant setting for resected, well-differentiated grade 2 or 3 pancreatic NETs with elevated risk scores, addressing the critical question of whether adjuvant chemotherapy can reduce recurrence rates and improve survival outcomes in high-risk patients.

Are Emerging Biomarkers Transforming Patient Care?

Biomarkers play an essential role in the clinical management of GEP-NETs, supporting diagnosis, prognostication, and therapeutic monitoring. Chromogranin A (CgA) is the most commonly used traditional biomarker, which can be elevated in 80-90% of cases. However, its specificity is limited by factors such as proton pump inhibitor use, renal dysfunction, and various non-malignant conditions. To overcome these limitations, multianalyte molecular assays like the NETest have been developed to evaluate circulating transcriptomatic signatures. The NETest demonstrates a diagnostic accuracy of approximately 91%, significantly outperforming CgA, and correlates well with tumor burden, grade, and imaging findings. This provides dynamic insight into disease progression and treatment response, with emerging data suggesting potential utility in surgical decision-making and early recurrence detection. Other investigational biomarkers include circulating tumor cells (CTCs) and microRNAs, which show promise as minimally invasive tools for monitoring disease status and treatment response, though standardization and clinical validation efforts remain ongoing. The integration of these novel molecular biomarkers into routine clinical practice has the potential to significantly enhance personalized management strategies for patients with GEP-NETs.

Could ADCs Revolutionize Targeted Therapy?

Novel therapeutic approaches for GEP-NETs include antibody-drug conjugates (ADCs), which combine the specificity of targeted antibodies with the cytotoxic potency of chemotherapy payloads. ADCT-701, a pyrrolobenzodiazepine dimer-based ADC targeting Delta-like 1 homolog (DLK1), is currently undergoing a first-in-human Phase I dose-escalation trial in adults with advanced neuroendocrine neoplasms. DLK1 is a transmembrane protein involved in developmental signaling that shows re-expression in certain neuroendocrine tumors and has been associated with proliferation, stemness, and poor prognosis. Another promising ADC, PEN-221, links an octreotate agonist to the cytotoxic payload DM1 and targets somatostatin receptor 2 (SSTR2). In a phase I/II clinical trial, PEN-221 demonstrated encouraging efficacy at the recommended phase II dose of 8.8 mg/m2, achieving a clinical benefit rate of 88.5% and median progression-free survival of 9 months. Among 26 evaluable patients, 23 (88.5%) achieved stable disease as their best response, and target lesion shrinkage was observed in 10 patients (38%). These emerging ADC platforms represent a novel therapeutic strategy that could potentially overcome the limitations of conventional therapies by delivering cytotoxic agents directly to tumor cells while sparing normal tissues.

How Will Precision Oncology Shape Future Treatments?

The evolving therapeutic landscape for GEP-NETs reflects significant advancements in precision oncology approaches, yet substantial challenges remain in optimizing patient outcomes. The inherent heterogeneity of these tumors, even among patients with similar clinical profiles, complicates treatment selection and sequencing decisions. While novel targeted agents have demonstrated promising efficacy in terms of response rates and progression-free survival, they often come with significant adverse events that may compromise quality of life, particularly problematic in patients with indolent disease who may live with their cancer for many years. High treatment costs and limited accessibility of advanced therapies such as PRRT and novel targeted agents present additional barriers to implementing optimal care globally. Furthermore, resistance mechanisms remain incompletely understood, and data on long-term disease control with newer modalities are still emerging, underscoring the need for continued translational research and refinement of therapeutic strategies. Could the development of more precise predictive biomarkers help identify which patients will derive the greatest benefit from specific therapies while experiencing minimal toxicity? How might the integration of molecular profiling into routine clinical decision-making change current treatment paradigms and improve patient selection for novel targeted approaches?

What Questions Remain Unanswered in GEP-NET Management?

Addressing these challenges requires a multidisciplinary, patient-centered approach that carefully balances efficacy against toxicity while considering individual patient characteristics and preferences. The optimal management of GEP-NETs necessitates integration of expertise from medical oncology, surgery, nuclear medicine, endocrinology, and radiology to develop personalized treatment plans. Key patient factors to consider include age, performance status, comorbidities, and symptom burden, which must be weighed alongside tumor-specific characteristics such as grade, differentiation, disease burden, metastatic distribution, and somatostatin receptor expression. Emerging molecular biomarkers like the NETest, which evaluates circulating transcriptomatic signatures with diagnostic accuracy around 91%, may provide dynamic insights into disease progression and treatment response that complement conventional imaging and biochemical assessments. The future of GEP-NET management lies in further refining precision oncology approaches through continued investment in high-quality clinical trials, global research collaboration, and development of innovative therapeutic combinations. As novel agents such as alpha-emitting radioligands, next-generation TKIs, and targeted ADCs advance through clinical development, they hold promise for transforming GEP-NETs from a manageable chronic condition into a potentially curable disease for at least some patient subgroups. How can we most effectively leverage emerging technologies and collaborative research networks to accelerate this transformation and improve outcomes for all patients with these complex neoplasms?

Looking toward the future, several critical research questions remain to be addressed in the field of GEP-NET management. How can we optimize treatment sequencing to maximize clinical benefit while minimizing cumulative toxicity over the often prolonged disease course? What combination strategies might yield synergistic effects that overcome resistance mechanisms and improve long-term outcomes? How can we better identify patients who will benefit from aggressive multimodality approaches versus those who might be best served by less intensive management strategies? The answers to these questions will likely emerge from ongoing and future clinical trials that incorporate robust translational components to elucidate mechanisms of response and resistance. The integration of novel molecular biomarkers, advanced imaging techniques, and patient-reported outcome measures into these studies will be essential to developing truly personalized treatment algorithms that balance efficacy, toxicity, quality of life, and resource utilization. As our understanding of GEP-NET biology continues to evolve, so too will our therapeutic approaches, with the ultimate goal of transforming these challenging neoplasms into chronic, controllable conditions with minimal impact on patients' daily lives and, for some, offering the possibility of durable remission or cure.

Summary

This comprehensive review examines the current state of gastroenteropancreatic neuroendocrine tumor (GEP-NET) management. The article discusses the rising incidence of these tumors, their complex biology, and varied clinical presentations. It details major therapeutic approaches, including somatostatin analogs, targeted therapies, and peptide receptor radionuclide therapy (PRRT). The text explores significant clinical trials, emerging biomarkers, and novel treatment strategies such as antibody-drug conjugates. Key findings from the PROMID, CLARINET, and NETTER trials are presented, along with discussions on treatment sequencing and the role of precision oncology. The review emphasizes the importance of multidisciplinary care and highlights ongoing challenges in optimizing patient outcomes.